WO2026008633 - INTRONIC TARGETED INSERTION OF TRANSGENES
National phase entry is expected:
Publication Number
WO/2026/008633
Publication Date
08.01.2026
International Application No.
PCT/EP2025/068693
International Filing Date
01.07.2025
Title **
[English]
INTRONIC TARGETED INSERTION OF TRANSGENES
[French]
INSERTION INTRONIQUE CIBLÉE DE TRANSGÈNES
Applicants **
NOVO NORDISK A/S
Inventors
RAHMAN, Shamim Herbert
FROGNE, Thomas
Priority Data
24185983.4
02.07.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2689 | |
| EPO | Filing, Examination, Granting | 10708 | |
| Japan | Filing, Examination, Granting | 2154 | |
| South Korea | Filing, Examination, Granting | 2066 | |
| USA | Filing, Examination, Granting | 6990 |
Total:
24,607
Contact Us
Abstract[English]
The invention relates to cells comprising a shutdown sequence and one or more transgene sequences inserted into both alleles of an intron of an endogenous gene. The invention relates to an optimised process for manufacturing of cells comprising a gene shutdown and, potentially, one or more transgene expression. The invention simplifies the shutdown process and improves shutdown efficiency.[French]
L'invention concerne des cellules comprenant une séquence d'inactivation et une ou plusieurs séquences transgéniques insérées dans les deux allèles d'un intron d'un gène endogène. L'invention concerne un procédé optimisé de fabrication de cellules faisant appel à une inactivation génique et, éventuellement, à une ou plusieurs expressions transgéniques. L'invention permet de simplifier le processus d'inactivation et améliore l'efficacité de celle-ci.